Regeneron Extends Agreement with BARDA to Provide Additional Supply of Ebola Treatment Inmazeb® for U.S. Preparedness

Regeneron Pharmaceuticals has extended its agreement with BARDA to supply additional doses of Inmazeb, its FDA-approved Ebola treatment, through 2031 for approximately $270 million. The company is also advancing maftivimab, a component of Inmazeb, as a potential monotherapy treatment for Bundibugyo virus disease in the current outbreak in the Democratic Republic of the Congo.